PET/CT based imaging biomarkers for response prediction of stage IV NSCLC treated with paclitaxel–carboplatin–bevacizumab with or without nitroglycerin

158P

  • Jong, de E.E.C.
  • Van Elmpt, W.
  • Leijenaar, R. T.H.
  • Groen, H.
  • Smit, E.
  • Boellaard, R.
  • Van der Noort, V.
  • Troost, E. G.C.
  • Lambin, P.
  • Dingemans, A.-M.

  • aDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

    bDepartment of Pulmonary Diseases, University Hospital Groningen (UMCG), Groningen, Netherlands

    cPulmonary Diseases, VUMC, Amsterdam, Netherlands

    dDepartment of Nuclear Medicine and Molecular Imaging, University Hospital Groningen (UMCG), Groningen, Netherlands

    eDepartment of Biometrics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

    fDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Institute of Radiooncolog, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany

    gPulmonology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

Journal of Thoracic Oncology 11(4):p S126-S127, April 2016. | DOI: 10.1016/S1556-0864(16)30268-4
Copyright © 2016 by the International Association for the Study of Lung Cancer
View full text|Download PDF